Painchek is a large holding in my strawman portfolio :) Here is the link to the investor conference happening 3rd - 4th August. The presentation deck is expected to be updated on Monday so there would be time to prepare questions before the presentation at 2:30pm. 

http://nwrconference.webflow.io/

Some questions I think will be interesting to ask management 

• If COVID-19 remain active in Victoria till October, will it delay Painchek's homecare pilot rollout with Novacare and Healthcare Australia or will the rollout happen regardless of COVID-19?
• For aged care customers that are hit with COVID-19 like Baptist agedcare and Anglicare, how are they using Painchek in their facilities? Have there been an increase in assessments from COVID-19 affected customers compared to others? 
• Have Painchek received enquires from additional distributors in UK after the webinar with National Care Forum and Care England? 

Those are some questions that would be of interest to get more clarity on. The first 2 are targeted towards COVID-19, I am interested to know how the Victorian outbreak affect the homecare pilot and how COVID-19 affected residential agedcare homes that use painchek. The last one is to see how much demand the UK business is getting from their "Care home for the future" webinars. 

It is still too early to know how the Phillips study gets carried out, as they recently opened communications with them to design the study. Painfaces will be delayed until Victoria gets a handle of the crisis which will be another delay. So they might move the study to another state if MCRI can't do it. I don't think PD can say too much into those.It will be interesting to see how he will answer the Q&A.